미시간의 소세포 폐암 임상 시험
소세포 폐암 관련 연구 26개가 미시간 내 여러 지역에서 참여자를 모집하고 있습니다.
미시간의 도시
공식 연구 텍스트(영어)
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- University of Michigan Hospitals, Ann Arbor
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT06805825A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Barbara Ann Karmanos Cancer Center, Detroit
- START Midwest, Grand Rapids
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07488676DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Veterans Affairs Ann Arbor Healthcare System, Ann Arbor
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07472517MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
- Karmanos Cancer Center (Wayne State University), Detroit
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT05903092A Study of MGC026 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06242470A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Henry Ford Hospital - Detroit /ID# 277218, Detroit
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT07155174A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 129, Detroit
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT05914116A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Henry Ford Health Cancer, Detroit
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 16. 업데이트됨 · NCT07218146Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
- V.A. Ann Arbor Healthcare System, Ann Arbor
- University of Michigan, Ann Arbor
피험자 모집 중2상
전 연령 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT05588388AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
- START Midwest, Grand Rapids
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT07454642177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- BAMF Health, Grand Rapids
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT07189871A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279955, Grand Rapids
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT07365241Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Corewell Health William Beaum Hosp, Royal Oak
피험자 모집 중1상
18세 ~ 100세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07006727Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
피험자 모집 중3상
18세 ~ 99세 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07778316A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- Karmanos Cancer Institute, Detroit
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT07325136Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
- Henry Ford Cancer Institute, Detroit
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT06922539A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 11. 업데이트됨 · NCT05592626A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Henry Ford Health System, Detroit
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT06203210Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Henry Ford Cancer- Detroit, Detroit
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 7. 28. 업데이트됨 · NCT07339059A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- START Midwest, Grand Rapids
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 22. 업데이트됨 · NCT06131840A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- START Midwest, Grand Rapids
- The Cancer and Hematology Centers, Grand Rapids
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 7. 9. 업데이트됨 · NCT07174583Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- Trinity Health Saint Joseph Mercy Ann Arbor, Ann Arbor
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 26. 업데이트됨 · NCT06598306Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- 외 14개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 3. 30. 업데이트됨 · NCT06769126Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 3. 11. 업데이트됨 · NCT06681220Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- START Midwest, Grand Rapids
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 2. 18. 업데이트됨 · NCT07030257JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Henry Ford Health System, Detroit
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 1. 9. 업데이트됨 · NCT05490472ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.